A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin As Adjunctive Therapy In Pediatric And Adult Subjects With Primary Generalized Tonic-clonic Seizures - Protocol A0081105

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin As Adjunctive Therapy In Pediatric And Adult Subjects With Primary Generalized Tonic-clonic Seizures - Protocol A0081105

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Tonic-clonic epilepsy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Aug 2018 This trial was completed in Denmark, according to European Clinical Trials Database.
    • 20 Jul 2018 Planned End Date changed from 30 Jun 2019 to 5 Jul 2019.
    • 20 Jul 2018 Planned primary completion date changed from 30 Jun 2019 to 5 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top